Quick Answer
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported Total Revenue of $93.47 million for fiscal year 2017.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$546.38M -76.3% |
-$309.85M -1.0% |
-$306.74M +2.4% |
-$314.25M -73.4% |
-$181.22M -716.3% |
$29.40M +134.9% |
| Diluted EPS | -$1.82 -14.5% |
-$1.59 -31.4% |
-$1.21 +13.6% |
-$1.40 -57.3% |
-$0.89 -623.5% |
$0.17 +130.9% |
| Total Assets | $784.08M -37.8% |
$1.26B -27.8% |
$1.75B -1.2% |
$1.77B -12.0% |
$2.01B +384.8% |
$413.98M +179.7% |
| Cash and Equivalents | $63.71M +15.1% |
$55.37M -69.2% |
$179.91M -44.7% |
$325.09M -29.4% |
$460.73M +464.5% |
$81.61M +175.5% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $5.35M -98.9% |
$506.59M -27.8% |
$701.30M +24.6% |
$562.90M -28.8% |
$790.99M +135.8% |
$335.49M +510.9% |
| R&D Expense | $97.31M -27.9% |
$134.92M -27.9% |
$187.17M -3.0% |
$193.00M +70.9% |
$112.90M +76.0% |
$64.15M +7.6% |
| Operating Income | -$553.86M -16.8% |
-$474.31M -41.8% |
-$334.47M -8.9% |
-$307.20M -46.0% |
-$210.44M -101.6% |
-$104.39M -3.8% |
| Gross Profit | $45.78M +22.8% |
$37.28M -29.4% |
$52.78M +7.6% |
$49.03M -16.7% |
$58.86M +80.7% |
$32.57M -5.8% |
| Shares Outstanding | 301.96M +2.6% |
294.42M +10.0% |
267.74M +18.2% |
226.50M +2.5% |
220.98M +14.9% |
192.29M +25.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $38.44M | -3.8% | -3.3% |
| Revenue (ASC 606) | September 30, 2025 | $38.44M | -3.8% | -3.3% |
| Net Income | September 30, 2025 | -$38.00M | +37.4% | +9.4% |
| Diluted EPS | September 30, 2025 | -$0.13 | +40.9% | +7.1% |
| Total Assets | September 30, 2025 | $803.16M | -44.6% | -2.7% |
| Cash and Equivalents | September 30, 2025 | $56.47M | -27.6% | +3.0% |
| Long-Term Debt | March 31, 2013 | $2.56M | -6.6% | -1.8% |
| Stockholders Equity | September 30, 2025 | $36.09M | -92.0% | -41.3% |
| R&D Expense | September 30, 2025 | $22.85M | -10.5% | +1.4% |
| Operating Income | September 30, 2025 | -$38.88M | +39.3% | +13.3% |
| Gross Profit | September 30, 2025 | $15.90M | +58.9% | +8.3% |
| Shares Outstanding | September 30, 2025 | 301.85M | +10.2% | +0.5% |
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported Total Revenue of $93.47 million for fiscal year 2017.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. showed an increase of +3.0% in Total Revenue compared to the prior fiscal year.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported Net Income of -$546.38 million for fiscal year 2025.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. showed a decrease of -76.3% in Net Income compared to the prior fiscal year.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported Diluted EPS of $1.82 per share (loss) for fiscal year 2025.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. showed a decrease of -14.5% in Diluted EPS compared to the prior fiscal year.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported Total Assets of $784.08 million for fiscal year 2025.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. showed a decrease of -37.8% in Total Assets compared to the prior fiscal year.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported Cash and Equivalents of $63.71 million for fiscal year 2025.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. showed an increase of +15.1% in Cash and Equivalents compared to the prior fiscal year.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported Long-Term Debt of $2.61 million for fiscal year 2012.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. showed a decrease of -6.2% in Long-Term Debt compared to the prior fiscal year.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported Stockholders Equity of $5.35 million for fiscal year 2025.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. showed a decrease of -98.9% in Stockholders Equity compared to the prior fiscal year.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported R&D Expense of $97.31 million for fiscal year 2025.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. showed a decrease of -27.9% in R&D Expense compared to the prior fiscal year.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported Operating Income of -$553.86 million for fiscal year 2025.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. showed a decrease of -16.8% in Operating Income compared to the prior fiscal year.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported Gross Profit of $45.78 million for fiscal year 2025.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. showed an increase of +22.8% in Gross Profit compared to the prior fiscal year.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported Shares Outstanding of 301.96 million shares for fiscal year 2025.
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC. showed an increase of +2.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: